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Type II endometrial cancers (uterine serous papillary and clear cell histologies) represent rare but highly aggressive variants of
endometrial cancer (EC). HER2 and EGFR may be differentially expressed in type II EC. Here, we evaluate the clinical role of HER2
and EGFR in a large cohort of surgically staged patients with type II (nonendometrioid) EC and compare the findings with those seen
in a representative cohort of type I (endometrioid) EC. In this study HER2 gene amplification was studied by fluorescence in situ
hybridisation (FISH) and EGFR expression by immunohistochemistry. Tissue microarrays were constructed from 279 patients with EC
(145 patients with type I and 134 patients with type II EC). All patients were completely surgically staged and long-term clinical follow
up was available for 258 patients. The rate of HER2 gene amplification was significantly higher in type II EC compared with type I EC
(17 vs 1%, Po0.001). HER2 gene amplification was detected in 17 and 16% of the cases with uterine serous papillary and clear cell
type histology, respectively. In contrast, EGFR expression was significantly lower in type II compared with type I EC (34 vs 46%,
P¼0.041). EGFR expression but not HER2 gene amplification was significantly associated with poor overall survival in patients with
type II EC, (EGFR, median survival 20 vs 33 months, P¼0.028; HER2, median survival 18 vs 29 months, P¼0.113) and EGFR
expression retained prognostic independence when adjusting for histology, stage, grade, and age (EGFR, P¼0.0197; HER2,
P¼0.7855). We conclude that assessment of HER2 gene amplification and/or EGFR expression may help to select type II EC patients
who could benefit from therapeutic strategies targeting both HER2 and EGFR.
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Endometrial carcinoma (EC) is the most common malignancy of
the female reproductive tract. Based on pathological and clinical
features, endometrial cancers are classified into two types.
Endometrioid or Type I EC, represents the majority of EC cases,
is oestrogen-related, usually arises in the setting of endometrial
hyperplasia, and tends to be biologically less aggressive (Hecht and
Mutter, 2006). Nonendometrioid or Type II EC, predominantly
uterine serous papillary carcinoma and clear cell endometrial
carcinoma, accounts for approximately 10% of ECs, is not
oestrogen-related, arises from atrophic endometrium, and
frequently presents in advanced stages with 5-year survival rates,
on average, between 30 and 40% (Abeler and Kjorstad, 1991; Goff
et al, 1994; Slomovitz et al, 2003). Extra-uterine disease is often
found in these patients even in the absence of myometrial invasion
(Abeler 1991; Goff et al, 1994; Bristow et al, 2001). Therefore,
comprehensive surgical staging is recommended for all patients
with type II EC regardless of the depth of myometrial invasion of
the tumour (Chan et al, 2003). These different clinical features are
paralleled by genetic distinctions. Type II ECs carry mutations of
independent sets of genes compared with type I EC. Type I EC is
associated with mutations in the PTEN tumour suppressor gene
and defects in DNA mismatch repair (Lax et al, 2000, Hecht and
Mutter, 2006). In contrast, p53 mutations, which are not usually
seen in type I EC have been identified in most cases of type II EC
(Acharya et al, 2005). Moreover, HER2 amplification/overexpres-
sion has been associated with type II EC (Hetzel et al, 1992; Santin
et al, 2005; Morrison et al, 2006; Grushko et al, 2008). However, the
exact frequency of HER2 amplification/overexpression in type II
EC remains controversial. HER2 gene amplification has been
reported to occur in 6 out of 28 (21%), 17 out of 58 (29%), or 11
out of 26 (42%) of patients with uterine serous papillary cancer
(Santin et al, 2005; Morrison et al, 2006; Grushko et al, 2008), and
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sHER2 protein overexpression was seen in 12 out of 68 (18%) of
cases (Slomovitz et al, 2008). In clear cell endometrial cancer HER2
amplification has been described in two out of nine (22%) and
three out of six (50%) of the reported cases (Morrison et al, 2006;
Grushko et al, 2007). Similar controversies exist regarding the
clinical relevance of the epidermal growth factor receptor (EGFR)
in EC in general and more specifically in type II EC. EGFR
expression has been demonstrated in 43–67% of patients with
endometrial cancer and its association with clinical outcome has
been explored with some studies demonstrating an association
between EGFR expression and poor clinical outcome (Khalifa et al,
1994; Scambia et al, 1994; Niikura et al, 1995) whereas others show
no association (Reinartz et al, 1994). Moreover, the clinical role of
EGFR expression specifically in type II EC has not yet been
studied. The current study represents a large consecutive series of
134 type II EC cases including 106 patients with uterine serous
papillary EC and 28 patients with clear cell EC, who underwent
surgery at Mayo Clinic between 1984 and 2004, respectively.
Patients at risk of relapse appear to benefit from adjuvant
chemotherapy, and responses to paclitaxel- and platinum-based
regimens have been reported in patients with advanced disease
(Hoskins et al, 2001; Ramondetta et al, 2001). Importantly,
however, target-based treatment approaches have not yet been
explored in type II EC. Recently, we were able to demonstrate
significant preclinical activity of a dual HER2 and EGFR kinase
inhibitor in endometrial cancer cell lines with HER2 amplification
or EGFR expression (Konecny et al, 2008). In an effort to
obtain a better understanding of the clinical role of HER2 and
EGFR in type II EC we studied HER2 gene amplification and
EGFR expression in a large cohort of patients with type II EC who
were all surgically staged and compared these findings with
those seen in a representative cohort of type I endometrioid EC
treated during the same time period. These studies were intended
to help characterise a subset of type II endometrial cancer
patients most likely to benefit from target-based treatment
approaches.
MATERIALS AND METHODS
Upon approval from the Institutional Review Board at Mayo
Clinic, we identified 137 patients from our database who under-
went surgery for type II endometrial cancer at Mayo Clinic
between May 1984 and December 2004. Next, we randomly
selected 150 patients who underwent surgery for endometrioid
endometrial cancer during the same time period. Of the 287
patients included in this study, 279 patients (97%) had archived
paraffin-embedded tissue available for analysis of HER2 gene
amplification and EGFR expression. All patients were completely
surgically staged and long-term clinical follow up was available for
258 patients (125 patients with type I EC and 133 patients with type
II EC). Tissue microarrays were created for each histological
subtype. All patients had a hysterectomy and removal of existing
adnexal structures and no other malignancy was diagnosed within
5 years before or after the diagnosis of endometrial cancer. Staging
was defined according to the International Federation of
Obstetricians and Gynecologists (FIGO) surgical staging system.
For patients treated before 1988, stage was determined retro-
spectively on the basis of the surgical and pathologic assessments.
The histological classification was according to the World Health
Organization classification. Architectural grading was based on the
degree of glandular differentiation in accordance with the FIGO
guidelines. All surgical procedures were the responsibility of a
gynaecologic oncologist. Lymphadenectomy was performed in
patients considered by the surgeon to be at risk for lymph node
metastasis, according to the histological grade and subtype, as well
as primary tumour diameter and the depth of myometrial invasion
as determined by an intraoperative analysis of frozen tissue
sections. Postoperative adjuvant radiotherapy consisted of external
pelvic, para-aortic, or abdominal irradiation or vaginal
brachytherapy or a combination of these.
Tissue specimens and tissue microarray
For tissue microarray construction, a hematoxylin and eosin
(H&E) stained histology slide from each patient’s archival tumour
block was reviewed to identify and mark the location of tumour
and normal components. The markings were transferred to the
corresponding tissue block. Marked donor blocks were cored into
the recipient master block according to a grid map with 0.8-mm
spacing from the center of one core to the center of the next core
either manually for the type I endometrial cancer tissue micro-
arrays (TMAs) or by use of an automated Beecher ATA 27 Tissue
Arrayer for the type II endometrial cancer TMAs (Beecher
Instruments Inc., Silver Spring, MD, USA). The tissue microarray
blocks constructed from the study tumours incorporated either
one tumour core and one normal tissue core (type I endometrial
cancer TMAs) or up to three tumour cores (type II endometrial
cancer TMAs) from an archival block for each subject. Each core
was 0.6mm in diameter. Cores were arrayed into grids of either
100 cores (type I endometrial cancer TMAs) or 300 cores (type II
endometrial cancer TMAs) in master blocks. After construction,
tissue microarray blocks were sealed with paraffin and stored at
41C. Sections (5mm thick) were cut from the tissue microarray
master blocks, mounted on superfrost slides, and assayed for
HER2 gene amplification and EGFR expression. HER2 FISH assays
were performed using the PathVysion assay (Abbott-Vysis Inc.,
Des Plaines, IL, USA) as described elsewhere (Press et al, 2002).
A slide was stained with H&E to confirm the presence of invasive
tumour. The corresponding area of invasive carcinoma was
enumerated on the FISH slides after hybridisation was complete.
Slides were evaluated for HER2 gene amplification by determining
the HER2/CEP17-signal ratio in at least 20 tumour nuclei as
required by the FDA original approval. If the ratio was o2.0, the
specimen was considered to lack gene amplification. For ratios
near the cutoff value (i.e., 1.8–2.2), an additional 20 nuclei were
evaluated by the same analyst and the ratio was recalculated. In
these cases a second analyst also scored at least 40 tumour cell
nuclei and if the ratios were both in agreement, the case recorded.
All assessments of HER2 status were made by a board-certified
pathologist with extensive experience in HER2 FISH testing (MFP).
EGFR expression was assessed by IHC and EGFR staining was
solely assessed in the glandular components of the endometrial
tumour tissue by a board-certified pathologist specialised in
gynaecologic malignancies (GLK). A polyclonal rabbit antibody to
the C-terminus epitope of EGFR was obtained from Santa Cruz
Biotechnology, Santa Cruz, CA, USA (cat. no. 1005; dilution
1:250). Tissue sections were microwave-heated for 5min in an
800-W oven in citrate buffer (0.1mM, pH 6.0). Sections were then
incubated at room temperature overnight with primary antibody.
Immunostaining was performed with the avidin–biotin complex
method (Vector, Burlingame, CA, USA). Negative controls
consisted of substituting normal serum for primary antibodies.
For tissue microarray analysis images of H&E and EGFR stains
were scanned with the Bliss Imaging System (Bacus Laboratories,
Inc, Lombard, IL, USA). The x and y coordinates of each core
within the grid were determined by the software and included as
part of the unique identifier, which was linked to the clinical
database. Only staining of the tumour cell membranes was
considered positive. Immunoreactivity was qualitatively scored
by interpreting the staining intensity (negative; weak, moderate, or
strong staining) and the percentage of positive tumour cells per
core (p25%; 425–50%; 450–75%; and 475%). Tissues were
graded positive for EGFR expression with X moderate staining
intensity in 425% of the cells examined.
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Overall survival was defined as the time to death from any cause.
Patients were censored on the date of last contact if a treatment
failure event had not been observed. Unadjusted survival was
assessed by the Kaplan–Meier method. Log-rank statistic was used
for outcome comparison in univariate analysis. Cox regression
analysis was used to estimate hazard ratios and their 95%
confidence intervals in multivariate analysis adjusted for histology
type, FIGO stage, tumour grade, and age. All reported P-values
and confidence intervals are from two-sided tests. Because
well-established and replicated cutoffs for the expression status
of EGFR in endometrial cancer were not available, we made the a
priori choice to analyse and report the scores as dichotomised
values.
RESULTS
The current study is an observational study in which we compared
the pattern of HER2 gene amplification and EGFR expression
between a cohort of 134 consecutive patients with type II ECs (106
uterine serous papillary and 28 clear cell type histologies) and a
representative group of 145 patients with type I EC treated over the
same time period. Patients with clear cell and uterine serous
papillary histology had a significantly worse OS when compared
with endometrioid EC cases (Figure 1A) and in patients with type
II EC FIGO stage was a significant predictor of OS (Figure 1B).
Tissue microarrays were constructed from the 279 available
tumour specimens for each histological subtype and HER2 as well
as EGFR status were assessed by FISH and IHC, respectively. The
use of tissue microarrays allowed us to obtain technically evaluable
results for HER2 in 275 (99%) and for EGFR in 255 (91%) of the
279 patients, respectively (Table 1). HER2 gene amplification was
significantly higher in type II EC when compared with type I EC
(17 vs 1.4%, Po0.001). HER2 gene amplification was seen in 18
(17%) of the 105 evaluable uterine serous papillary EC specimens,
and in four (16%) of the 25 evaluable clear cell EC specimens.
Type I EC demonstrated a lower than expected rate of HER2 gene
amplification (1.4%). Furthermore, we were not able to detect an
increase in the rate of HER2 gene amplification from grade 1 to
grade 3 endometrioid ECs (Table 2). The mean HER2/CEP17 signal
ratio was 3.61 (range, 2.00–8.89) in samples with HER2 gene
amplification. The mean number of HER2 signals per cell, mean
number of CEP17 signals per cell, and the HER2/CEP17 ratios for
each HER2-positive case are shown in Table 3.
In contrast to the higher rate of HER2 gene amplification in type
II EC, EGFR expression was significantly lower in type II EC
compared with type I EC (34 vs 46%, P¼0.041; Table 1).
Moreover, the rate of EGFR expression was significantly lower in
grade 3 compared with grade 1/2 endometrioid EC (31 vs 52%,
P¼0.016). When analysing all 279 patients, there was a significant
increase in the rate of HER2 amplification, but not of EGFR
expression, from stage I to stage IV disease (HER2, P¼0.025;
EGFR, P¼0.667; Table 2). Similarly, we found a significant
increase in the rate of HER2 gene amplification from grade 1 to 3
tumours, and conversely a significant decrease in the rate of EGFR
expression from grade 1 to 3 tumours (P¼0.028 and P¼0.016,
respectively; Table 2). HER2 gene amplification was associated
with significantly worse OS in univariate analysis (HER2, Po0.001;
Figure 2A) but did not retain independent prognostic significance
when accounting for grade, stage, age, and histology (HER2,
P¼0.860). EGFR was not prognostically relevant in the entire
cohort of 279 patients including both type I and Type II EC
(P¼0.804; Figure 2B). When analysing only patients with type II
endometrial cancer EGFR expression, but not HER2 gene
amplification, was statistically significantly associated with worse
OS when compared with those patients with either non-HER2
amplified or non-EGFR expressing EC (HER2, median OS 18 vs 29
months, P¼0.113; EGFR, median OS 20 vs 33 months, P¼0.028;
Figure 3A and B). EGFR-retained independent prognostic
significance for OS in type II EC when accounting for age and
stage in multivariate analysis (EGFR, risk ratio 1.81, 95% CI 1.10 – 2.99,
P¼0.0197; Table 4).
DISCUSSION
Our understanding of the pathogenesis or the optimal treatment of
uterine serous papillary and clear cell EC is limited. The existing
lack of prospective clinical trials assessing adjuvant therapy in
these aggressive variants of EC and the absence of targeted
treatment approaches reflects at least in part the low incidence of
type II EC with the accompanying limited single institutional
experiences. However, a reasonable estimate would predict that
3000–4000 women in the United States alone will be diagnosed
with type II EC during 2008 and an estimated 55–65% will die,
accounting for approximately 18–24% of all endometrial cancer-
related deaths (Podratz and Mariani, 2003). Thus the absence of
randomised clinical trials for one of the most aggressive
gynaecologic malignancies appears unacceptable.
Evidence for a role of HER2 and EGFR in the pathogenesis of
various cancers has led to the rational design and development
of agents that selectively target HER2 and EGFR. In unselected
patients with endometrial cancer, HER2 amplification/overexpres-
sion represents a rare event. However, the findings of our
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Figure 1 (A) Kaplan–Meier survival plots of all type I and type II endometrial cancer patients with available clinical follow-up information (n¼258)
according to the histology type and (B) Kaplan–Meier survival plots among type II endometrial cancer patients with available follow up (n¼133) according
to FIGO stage.
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HER2 amplification/overexpression is seen more commonly in
well-defined subtypes of EC such as uterine serous papillary
cancer or clear cell cancer. Trastuzumab (Herceptin) a humanised
anti-HER2 antibody has recently been approved for the adjuvant
treatment of HER2-overexpressing (3þ IHC) or FISH-positive
primary breast cancers based on a highly significant 52%
reduction in the risk of recurrence in node-positive HER2-positive
primary breast cancer (Romond et al, 2005). More recent advances
in biotechnology have led to the development of the oral dual
tyrosine kinase inhibitor lapatinib, which has been shown to have
significant activity in trastuzumab-refractory breast cancer (Geyer
et al, 2006). Encouraged by these clinical response data which were
generated in breast cancer patients with HER2 amplification/
overexpression, we comprehensively assessed the rate of HER2
gene amplification in a large consecutive series of patients with
uterine serous papillary and clear cell endometrial cancers. These
studies were intended to define a subset of type II EC patients who
Table 1 Patient and disease characteristics of endometrial cancer patients with endometrioid, uterine serous papillary, and clear cell type histology
Endometrioid Uterine serous papillary Clear cell
No. Valid % No. Valid % No. Valid %
145 106 28
Median age (range) 65 (38–90) 68 (47–93) 68 (41–86)
Median follow up (months) 83 (0.3–270) 20 (0.1–162) 38 (0.2–180)
Surgery dates (range) 3/84–3/04 2/84–12/04 3/88–5/04
Stage
I 97 (67) 30 (29) 13 (46)
II 11 (8) 0 (0) 0 (0)
III 22 (15) 17 (17) 7 (25)
IV 14 (10) 56 (54) 8 (29)
Grade
1 51 (35) 1 (1) 2 (7)
2 54 (37) 1 (1) 4 (14)
3 40 (28) 87 (98) 22 (79)
HER2 Status
Positive 2/143 (1.4) 18/105 (17) 4/25 (16)
EGFR status
Positive 60/130 (46) 36/101 (36) 6/24 (25)
Table 2 Associations between HER2 gene amplification or EGFR
expression and disease characteristics including type of histology, FIGO
stage, and grade
Patients HER2-positive EGFR-positive
No. Valid % No. Valid % No. Valid %
Histology*
Endometrioid grade 1 51 (18) 1/50 (2) 27/48 (56)
Endometrioid grade 2 54 (20) 1/53 (2) 22/47 (47)
Endometrioid grade 3 40 (15) 0/40 (0) 11/35 (31)
Clear cell 28 (10) 4/25 (16) 6/24 (25)
Serous papillary 106 (37) 18/105 (17) 36/101 (36)
FIGO stage**
I 140 (52) 8/140 (6) 54/127 (43)
II 11 (4) 0/11 (0) 4/9 (44)
III 46 (17) 3/46 (7) 14/43 (33)
IV 77 (27) 13/77 (17) 27/72 (38)
Grade***
1 54 (21) 1/54 (2) 28/51 (55)
2 59 (23) 2/59 (3) 23/52 (44)
3 148 (56) 17/148 (11) 45/138 (33)
Unknown data: grade (n¼17), stage (n¼4), HER2 (n¼6), EGFR (n¼24). * w
2 test
type I versus type II: Po0.001 for HER2, and P¼0.041 for EGFR. ** w
2 test:
P¼0.025 for HER2, and P¼0.667 for EGFR. *** w
2 test: P¼0.028 for HER2, and
P¼0.016 for EGFR.
Table 3 Mean number of HER2 and Cep17 signals per cell, as well as the
HER2/Cep17 ratios for each HER2-positive case
HER2/Cep17
ratio
HER2
signals/cell
Cep17
signals/cell Histology
2.00 3.40 1.70 USPC
2.03 3.95 1.95 CC
2.05 5.73 2.80 USPC
2.06 3.40 1.65 USPC
2.06 5.57 2.70 CC
2.08 5.00 2.40 USPC
2.28 4.45 1.95 USPC
2.55 6.75 2.65 USPC
2.63 5.4 1.55 USPC
2.71 3.25 1.20 USPC
2.88 4.75 1.65 USPC
2.98 5.95 2.00 USPC
3.16 8.05 2.55 USPC
3.48 5.40 1.55 CC
3.93 5.70 1.45 USPC
3.98 8.95 2.25 USPC
4.21 13.25 3.15 USPC
4.23 8.25 1.95 E
4.41 7.50 1.70 USPC
4.58 13.75 3.00 USPC
6.59 10.55 1.60 E
7.15 17.55 2.45 CC
8.89 15.55 1.75 USPC
USPC¼uterine serous papillary cancer; CC¼clear cell cancer; E¼endometrioid
endometrial cancer. Missing data: n¼1.
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smay benefit from a selective HER2 inhibitor or a dual kinase
inhibitor, which targets both HER2 and EGFR. The aggressive
nature of type II EC is confirmed in our study by the observation
that two out of three patients diagnosed with uterine serous
papillary and one of two diagnosed with clear cell cancer had
extra-uterine disease at the time of primary surgery. HER2 gene
amplification was found in 17 and 16% of the serous papillary and
clear cell EC cases, respectively. Earlier studies have reported
higher rates of HER2 gene amplification in uterine serous papillary
EC. The most recent study conducted by Grushko et al. detected
HER2 gene amplification in 6 out of 28 (21%) patients with serous
papillary and 3 out of 6 (50%) of clear cell EC (Grushko et al,
2008). This study cohort of that report, however, differed
considerably from the consecutive series in our study, as it
included patients with measurable stage III, stage IV, or recurrent
endometrial cancer that were enrolled in GOG study no. 177
evaluating the role of doxorubicin and cisplatin with or without
paclitaxel in advanced endometrial cancer. Santin et al. reported
HER2 gene amplification in 14 out of 30 (47%) patients with
uterine serous papillary cancer. Importantly, however, of the 30
patients included in his study, 12 were African-American patients
of whom eight (67%) showed amplification by FISH compared
with six (33%) of the remaining 18 Caucasian patients. Informa-
tion on the patient’s race was not collected in our current study,
yet possible differences in patient populations may account for the
reported discrepancy in the rate of HER2 gene amplification
between both studies. Importantly, previous studies have reported
a higher incidence of serous papillary endometrial cancer and a
higher rate of HER2 gene amplification in African-American
patients when compared with Caucasian patients (Maxwell and
Risinger, 2006; Morrison et al, 2006). When combining the results
of the aforementioned studies, which have all used FISH for
assessment of HER2 status, HER2 gene amplification, at average,
was detected in 54 out of 222 (24%) patients with serous papillary
EC. In contrast to our low rate of HER2 gene amplification in type I
EC, other groups have been able to demonstrate HER2 gene
amplification in 9 out of 363 (4%) of unselected type I EC and in 5
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Figure 2 Kaplan–Meier survival plots of all type I and type II endometrial cancer patients with available clinical follow-up information (n¼258) according
to HER2 status (A), and EGFR status (B).
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Figure 3 Kaplan–Meier survival plots of all type II endometrial cancer patients with available clinical follow-up information (n¼133) according to HER2
status (A), and EGFR status (B).
Table 4 Prognostic significance of EGFR status in type II endometrial
cancer patients using multivariate analysis
Parameter Risk ratio (95% CI) Wald test
Age 1.06 (1.03, 1.09) P¼0.0002
Stage
1–2 (reference) 1.0
3 3.23 (1.24, 8.40) P¼0.0160
4 11.8 (5.33, 26.2) Po0.0001
EGFR
Negative (reference) 1.0
Positive 1.81 (1.10, 2.99) P¼0.0197
A stepwise method was used for variable selection. EGFR expression, stage, and age
were selected as significant prognostic factors.
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(Morrison et al, 2006). We may not have been able to confirm
these rates possibly because of differences in the patient
populations or because of the smaller sample size of type I ECs
in our study. Previous data on the rate of HER2 gene amplification
in clear cell EC (22–50%) are unquestionably limited by the small
number of samples investigated so far. The actual rate of HER2
gene amplification in clear cell EC may thus be somewhat lower
according to the findings of our study.
The clinical role of EGFR has not been studied well in EC,
moreover this is the first study to evaluate the incidence and
prognostic relevance of EGFR expression in type II EC.
Importantly, EGFR may have a dual role in EC, such that high
EGFR expression in type I EC was associated with low grade and
favourable outcome. In contrast, EGFR expression in type II EC
was associated with high grade and adverse clinical outcome.
Therefore, EGFR expression did not appear to impact disease
progression in well-differentiated endometrioid endometrial
cancer, but did seem to affect disease progression in undifferentiated
nonendometrioid endometrial cancer. To date EGFR inhibitors
have not been clinically tested in type II EC. Importantly, the
clinical benefit observed with anti-EGFR tyrosine kinase inhibitors
(TKIs) across different disease entities has been variable. For
example, EGFR TKIs are largely inactive in colorectal cancer and
breast cancer (Tan et al, 2004; Baselga and Arteaga, 2005).
Nevertheless, two of these drugs, gefitinib and erlotinib, have
demonstrated clinical activity in non small cell lung cancer and
responses have been observed in patients with advanced
pancreatic cancer and in head-and-neck cancer (Baselga, 2006).
Preclinical data suggest that EGFR inhibitors may be clinically
active in well-defined subgroups of endometrial cancer patients
with HER2 gene amplification or high levels of EGFR expression
(Konecny et al, 2008). Importantly, however, EGFR receptor
expression levels when assessed by IHC have not been able to
predict a response to EGFR inhibitors in other tumour types.
Earlier clinical studies in other disease entities show that potential
markers of sensitivity to EGFR TKIs include the presence of EGFR
gene amplification, mutations of the EGFR gene, and increased
expression of EGFR ligands (Baselga and Arteaga, 2005). Earlier
studies have demonstrated significantly higher expression levels of
the EGFR ligands TGF-a and amphiregulin in EC compared with
normal endometrium (Pfeiffer et al, 1997; Ejskjaer et al, 2007). The
roles of EGFR gene amplification or mutations in EC, however,
have not yet been studied.
Although HER2 gene amplification or EGFR expression each can
only be detected in small subsets of patients with type II EC,
collectively, 46% of the patients with type II EC demonstrated
HER2 gene amplification and/or EGFR expression in our study.
The pooling of national or global patient resources should allow
the realisation of prospective clinical trials (that stratify for HER2
gene amplification or EGFR expression) for patients with type II
EC that may involve HER2 and EGFR tyrosine kinase inhibitors in
well-defined subsets with HER2 gene amplification or EGFR
expression.
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